more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.19 USD

+0.75 (7.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $11.24 +0.05 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy

by Zacks Equity Research Published on August 26,2022

Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.

Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

by Zacks Equity Research Published on August 05,2022

Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research Published on July 22,2022

Smart Beta ETF report for XBI

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

by Zacks Equity Research Published on June 22,2022

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

Iovance (IOVA) Down After Announcing Data From Melanoma Study

by Zacks Equity Research Published on May 27,2022

Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.

Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track

by Zacks Equity Research Published on May 06,2022

Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.

Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why

by Zacks Equity Research Published on April 08,2022

Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.

Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August

by Zacks Equity Research Published on April 06,2022

Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.

Iovance (IOVA) to Start Clinical Studies for TIL Therapy

by Zacks Equity Research Published on March 16,2022

Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

by Zacks Equity Research Published on February 25,2022

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3

by Zacks Equity Research Published on November 05,2021

Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.

Iovance Biotherapeutics (IOVA) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on November 03,2021

Iovance Biotherapeutics (IOVA) has been struggling lately, but the selling pressure may be coming to an end soon.

IOVAPositive Net Change

medical

Wall Street Analysts Think Iovance Biotherapeutics (IOVA) Could Surge 52%: Read This Before Placing a Bet

by Zacks Equity Research Published on October 27,2021

The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Iovance Biotherapeutics (IOVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

IOVAPositive Net Change

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 49% as Wall Street Analysts Expect?

by Zacks Equity Research Published on October 11,2021

The consensus price target hints at a 49% upside potential for Iovance Biotherapeutics (IOVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

IOVAPositive Net Change

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

by Zacks Equity Research Published on September 16,2021

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Implied Volatility Surging for Iovance (IOVA) Stock Options

by Zacks Equity Research Published on August 16,2021

Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.

IOVAPositive Net Change

Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research Published on August 06,2021

Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.

biotechs

Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy

by Zacks Equity Research Published on June 30,2021

Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.